Staar Surgical Co: Form 10-Q for the period ended Mar 31, 2023
Filed with the SEC on May 3, 2023 and accepted by EDGAR at May 3, 2023, 16:12 ET.
Management's discussion and analysis
As filed, 18,946 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
The matters addressed in this Item 2 that are not historical information constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Readers can recognize forward-looking statements by the use of words like “anticipate,” “estimate,” “expect,” “intend,” “plan,” “believe,” “will,” “should,” “forecast” and similar expressions in connection with any discussion of future operating or financial performance. In particular, these include statements about any of the following: any projections of or guidance as to earnings, revenue, sales, profit margins, expense rate, cash, effective tax rate, product mix, capital expense or any other financial items; the expected impact of the COVID-19 pandemic and related public health measures (including but not limited to their impact on sales, operations or clinical trials globally), the plans, strategies, and objectives of management for future operations or prospects for achieving such plans; statements regarding new, existing, or improved products, including but not limited to, expectations for success of new, existing, and improved products in the U.S. or international markets or government approval of a new or improved products; commercialization of new or improved products; future economic conditions or size of market opportunities; expected costs of operations; statements of belief, including as to achieving 2023 business plans; expected regulatory activities and approvals, product launches, and any statements of assumptions underlying any of the foregoing.
Although we believe that the expectations reflected in these forward-looking statements are reasonable, such statements are inherently subject to risks and we can give no assurance that our expectations will prove to be correct. Actual results could differ from those described in this report because of numerous factors, many of which are beyond our control. These factors include, without limitation, those described in our Annual Report on Form 10-K in “Item 1A. Risk Factors” filed on February 23, 2023. We undertake no obligation to update these forward-looking statements after the date of this report to reflect future events or circumstances or to reflect actual outcomes.
The following discussion should be read in conjunction with the audited consolidated financial statements of STAAR, including the related notes, provided in this report.
Overview
STAAR Surgical Company designs, develops, manufactures, and sells implantable lenses for the eye and companion delivery systems used to deliver the lenses into the eye. We are the world’s leading manufacturer of intraocular lenses for patients seeking refractive vision correction, and we also make lenses for use in surgery to treat cataracts. All the lenses we make are foldable, which allows the surgeon to insert them into the eye through a small incision during minimally invasive surgery. Refractive surgery is performed to treat the type of visual disorders that have traditionally been corrected using eyeglasses or contact lenses. We refer to our lenses used in refractive surgery as “implantable Collamer® lenses” or “ICLs.” The field of refractive surgery includes both lens-based procedures, using products like our ICL family of products, and laser-based procedures like LASIK. Successful refractive surgery can correct common vision disorders such as myopia, hyperopia, and astigmatism. Cataract surgery is a common outpatient procedure where the eye’s natural lens that has become cloudy with age is removed and replaced with an artificial lens called an intraocular lens (“IOL”) to restore the patient’s vision. STAAR employs a commercialization strategy that strives for sustainable profitable growth. Our goal is to position our refractive lenses throughout the world as primary and premium solutions for patients seeking visual freedom from wearing eyeglasses or contact lenses while achieving excellent visual acuity through refractive vision correction. We position our cataract IOL lenses used in surgery that treats cataracts based on quality and value.
Recent Developments
STAAR achieved 20% growth in both ICL units and sales in the first quarter, compared to the first quarter of 2022, with unit growth in APAC up 19%, EMEA up 18%, and the U.S. up 78%. In China, ICL procedure volumes increased strongly in the first quarter of 2023 with end-market procedures reaching a record level. Due to our growth investments and the increase in stock-based compensation we now anticipate operating margin for fiscal year 2023 will be approximately 10%, at the middle of the range of our 5-year average. We anticipate accelerating sales momentum as we move through the year. We are therefore raising our outlook for fiscal 2023 net sales from $340 million to approximately $348 million, which includes approximately $3 million of Other Product sales in the first quarter. Our updated outlook represents 28% global ICL sales growth year over year.
Regarding our Other Products business, in March we issued a Field Safety Notice to affected customers in Japan, France, Germany, Poland, and Italy to stop using our KS-SP preloaded acrylic IOL product manufactured by STAAR Japan, used in cataract procedures (unrelated to the EVO ICL). This was done as a precautionary measure in response to a Field Safety Notice issued by another company regarding a similarly manufactured product. Our communication asked customers to stop using the KS-SP product until we determine the specific root cause, and is not considered a product recall. STAAR will update customers after completing its investigation. As of March 31, 2023, we had approximately $1.2 million of KS-SP inventory.
Critical Accounting Estimates
This Management’s Discussion and Analysis of Financial Condition and Results of Income discusses and analyzes data in our unaudited Condensed Consolidated Financial Statements provided in this report, which we have prepared in accordance with U.S. generally accepted accounting principles. Preparation of these financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosure of contingent assets and liabilities. Management bases its estimates on historical experience and on various other assumptions that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Senior management has discussed the development, selection and disclosure of these estimates with the Audit Committee of our Board of Directors. Actual conditions may differ from our assumptions and actual results may differ from our estimates.
Management believes that there have been no significant changes during the three months ended March 31, 2023 to the items that we disclosed as our critical accounting estimates in Management’s Discussion and Analysis of Financial Condition and Results of Operations in our Annual Report on Form 10-K for the fiscal year ended December 30, 2022.
Results of Operations
The following table shows the percentage of our total sales represented by certain items reflected in our Condensed Consolidated Statements of Income for the periods indicated.
| Percentage of Net Sales for Three Months March 31, 2023 | April 1, 2022 | |
|---|---|---|
| Net sales | 100.0% | 100.0% |
| Cost of sales | 21.7% | 22.1% |
| Gross profit | 78.3% | 77.9% |
| General and administrative | 24.7% | 18.9% |
| Selling and marketing | 35.8% | 27.3% |
| Research and development | 14.0% | 12.6% |
| Total selling, general and administrative | 74.5% | 58.8% |
| Operating income | 3.8% | 19.1% |
| Total other income (expense), net | 2.6% | (0.9)% |
| Income before income taxes | 6.4% | 18.2% |
| Provision for income taxes | 2.7% | 3.0% |
| Net income | 3.7% | 15.2% |
Net Sales
The following table presents our net sales, by product (dollars in thousands):
| Three Months Ended March 31, 2023 | April 1, 2022 | Percentage Change 2023 vs. 2022 | |
|---|---|---|---|
| ICLs | $70,625 | $58,675 | 20.4% |
| Other product sales: | |||
| Cataract IOLs | 1,476 | 2,902 | (49.1)% |
| Other surgical products | 1,427 | 1,623 | (12.1)% |
| Total other product sales | 2,903 | 4,525 | (35.8)% |
| Net sales | $73,528 | $63,200 | 16.3% |
Net sales for the three months ended March 31, 2023 increased 16% from the same period of 2022. The increase in net sales was primarily due to increased ICL sales of $12.0 million. Changes in foreign currency unfavorably impacted net sales by $2.0 million.
Total ICL sales for the three months ended March 31, 2023 increased 20% from the same period of 2022, with unit increase of 20%. The APAC region sales increased by 20%, with unit growth up 19%, due to sales growth in other APAC regions up 34%, China up 25%, Korea up 19% and Japan up 6%. The Europe, Middle East, Africa and Latin America region sales increased 10% with unit increase of 18%, due to sales growth in in our distributor markets up 16% and direct markets up 6%. The North America region sales increased 56%, with unit growth up 60%, primarily due to sales growth in the U.S. up 71%. In late March 2022, the U.S. started to sell EVO ICLs. Changes in foreign currency unfavorably impacted ICL sales by $1.7 million for the three months ended March 31, 2023, which impacted our Japan and Europe, Middle East and Africa markets. ICL sales represented 96.1% and 92.8% of our total sales for the three months ended March 31, 2023 and April 1, 2022, respectively.
Other product sales, includes cataract IOLs, delivery systems and normal recurring sales adjustments such as sales return allowances. As a result of third-party materials and supply chain challenges that affect our cataract IOLs and associated delivery devices, we will no longer manufacture cataract IOLs, though we will continue to support these products through the end of 2023, as supplies permit. We do not expect this decision to have a significant impact to revenue growth in future years. Other product sales for the three months ended March 31, 2023, decreased 36% from the same period of 2022, due to primarily to decreased sales of cataract IOLs. Changes in foreign currency unfavorably impacted other product sales by $0.3 million for the three months ended March 31, 2023. Other product sales represented 3.9% and 7.2% of our total sales for the three months ended March 31, 2023 and April 1, 2022, respectively.
Gross Profit
The following table presents our gross profit and gross profit margin (dollars in thousands):
| Three Months Ended March 31, 2023 | April 1, 2022 | Percentage Change 2023 vs. 2022 | |
|---|---|---|---|
| Gross profit | $57,562 | $49,264 | 16.8% |
| Gross margin | 78.3% | 77.9% |
Gross profit for the three months ended March 31, 2023 increased 16.8% from the same period of 2022. Gross profit margin increased to 78.3% of revenue for the three months ended March 31, 2023 compared to 77.9% of revenue for the three months ended April 1, 2022, due mainly to product and geographic sales mix, partially offset by increased period costs associated with manufacturing projects.
General and Administrative Expense
The following table presents our general and administrative expenses (dollars in thousands):
| Three Months Ended March 31, 2023 | April 1, 2022 | Percentage Change 2023 vs. 2022 | |
|---|---|---|---|
| General and administrative expense | $18,098 | $11,940 | 51.6% |
| Percentage of sales | 24.7% | 18.9% |
General and administrative expenses for the three months ended March 31, 2023 increased 51.6% from the same period of 2022 due to increased bonus and stock-based compensation expenses, Japan one-time employee benefits, outside services, salary-related and payroll tax expenses and facility costs.
Selling and Marketing Expense
The following table presents our selling and marketing expenses (dollars in thousands):
| Three Months Ended March 31, 2023 | April 1, 2022 | Percentage Change 2023 vs. 2022 | |
|---|---|---|---|
| Selling and marketing expense | $26,354 | $17,270 | 52.6% |
| Percentage of sales | 35.8% | 27.3% |
Selling and marketing expenses for the three months ended March 31, 2023 increased 52.6% from the same period of 2022 due to increased advertising and promotional activities, especially in the U.S., sales commission expenses and trade shows and sales meetings expenses.
Research and Development Expense
The following table presents our research and development expenses (dollars in thousands):
| Three Months Ended March 31, 2023 | April 1, 2022 | Percentage Change 2023 vs. 2022 | |
|---|---|---|---|
| Research and development expense | $10,310 | $7,941 | 29.8% |
| Percentage of sales | 14.0% | 12.6% |
Research and development expenses for the three months ended March 31, 2023 increased 29.8% from the same period of 2022 due mainly to increased salary-related and payroll tax expenses and clinical expenses associated with our U.S. post-approval clinical trials.
Other Expense, Net
The following table presents our other expenses, net (dollars in thousands):
| Three Months Ended March 31, 2023 | April 1, 2022 | Percentage Change 2023 vs. 2022 | ||
|---|---|---|---|---|
| Other income (expense), net | $1,919 | $(586) | — | * |
| Percentage of sales | 2.6% | (0.9)% |
* Denotes change is greater than +100%.
The change in other income (expense), net for the three months ended March 31, 2023 and April 1, 2022, respectively, was due to increased interest income mainly due to our investments held available for sale and foreign exchange gains (primarily euro), for the three months ended March 31, 2023 compared to foreign exchange losses for three months ended April 1, 2022.
Income Taxes
The following table presents our income tax provision (dollars in thousands):
| Three Months Ended March 31, 2023 | April 1, 2022 | Percentage Change 2023 vs. 2022 | |
|---|---|---|---|
| Income tax provision | $2,009 | $1,925 | 4.4% |
The effective tax rates for the three months ended March 31, 2023 and April 1, 2022 were 42.6% and 16.7%, respectively. Our effective tax rates differ from the U.S. federal statutory rate of 21%, primarily due to the income taxes generated in foreign jurisdictions.
Our future effective income tax rate depends on various factors, such as changes in tax laws, regulations, accounting principles, or interpretations thereof, and the geographic composition of our pre-tax income. We carefully monitor these factors and adjust our effective income tax rate accordingly.
Liquidity and Capital Resources
We believe that current cash and cash equivalents, investments available for sale (“AFS”) and future cash flow from operating activities will be sufficient to meet our anticipated cash needs, including working capital needs, capital expenditures and contractual obligations for at least 12 months from the issuance date of the financial statements included in this quarterly report. Our financial condition at March 31, 2023 and December 31, 2021 included the following (in thousands):
| March 31, 2023 | December 30, 2022 | 2023 vs. 2022 | |
|---|---|---|---|
| Cash and cash equivalents | $89,968 | $86,480 | $3,488 |
| Investments available for sale | 127,324 | 139,061 | (11,737) |
| Total | $217,292 | $225,541 | $(8,249) |
| Current assets | $312,871 | $311,723 | $1,148 |
| Current liabilities | 47,063 | 51,716 | (4,653) |
| Working capital | $265,808 | $260,007 | $5,801 |
Cash and cash equivalents include cash and balances in deposits and money market accounts held at banks and financial institutions. Our investment policy primary objective is capital preservation while maximizing our return on investment. Investments available for sale may include U.S. government and corporate debt securities, commercial paper, certain certificates deposit and related security types, that are rated by two nationally recognized statistical rating organizations with minimum investment grade ratings of AAA to A-/A-1+ to A-2, or the equivalent. The maturity of individual investments may not extend 24 months from the date of purchase. There are also limits to the amount of credit exposure in any given security type. We do not have any off-balance sheet arrangements.
A summary of cash flows for the three months ended March 31, 2023 and April 1, 2022 was as follows (in thousands):
| Cash flows from: | Three Months Ended March 31, 2023 | April 1, 2022 |
|---|---|---|
| Operating activities | $(5,094) | $(4,610) |
| Investing activities | 9,933 | (2,539) |
| Financing activities | (1,361) | 894 |
| Effect of exchange rate changes | 10 | (384) |
| Net increase (decrease) in cash and cash equivalents | 3,488 | (6,639) |
| Cash and cash equivalents, at beginning of year | 86,480 | 199,706 |
| Cash and cash equivalents, at end of year | $89,968 | $193,067 |
For the three months ended March 31, 2023 net cash used by operating activities consisted of $14.3 million in working-capital changes partially offset by $6.5 million in non-cash items and net income of $2.7 million.
Starting in the second half of 2022, we decided to invest our cash in slightly higher yielding securities. For the three months ended March 31, 2023, net cash provided by investment activities was $10.0 million which consisted of $40.3 million of proceeds from the sale or maturity of investments AFS, partially offset by $27.4 million in purchases of investments AFS and $2.9 million in purchases of property, plant and equipment. For the three months ended April 1, 2022, net cash used in investment activity consisted of $2.5 million in purchases of property, plant and equipment.
Net cash used in financing activities for the three months ended March 31, 2023 was $1.4 million which consisted of $1.8 million to repurchase of employee common stock for taxes withheld, partially offset by $0.5 million of proceeds from the exercise of stock options. For the three months ended April 1, 2022, net cash provided by financing activities consisted of $0.9 million of proceeds from the exercise of stock options.
Commitments
Employment Agreements
The Company’s Chief Executive Officer entered into an employment agreement with the Company, effective January 1, 2023. He and certain officers have as provisions of their agreements certain rights, including continuance of cash compensation and benefits, upon a “change in control,” which may include an acquisition of substantially all of its assets, or termination “without cause or for good reason” as defined in the employment agreements.
Market risk
As filed, 242 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
During the three months ended March 31, 2023, there have been no material changes in the Company’s qualitative and quantitative market risk since the disclosure in the Company’s Annual Report on Form 10-K for the year ended December 30, 2022.
Controls and procedures
As filed, 3,362 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Disclosure Controls and Procedures
As of the end of the period covered by this report, we carried out an evaluation, under the supervision and with the participation of our management, including our CEO and CFO, of the effectiveness of the design and operation of the disclosure controls and procedures of the Company. Based on that evaluation, our CEO and CFO concluded, as of the end of the period covered by this quarterly report on Form 10-Q, that our disclosure controls and procedures were effective. For purposes of this statement, the term “disclosure controls and procedures” means controls and other procedures of the Company that are designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Securities Exchange Act (15 U.S.C. 78a et seq.) is recorded, processed, summarized and reported, within the time periods specified in the Securities and Exchange Commission’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Act is accumulated and communicated to the Company’s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.
Our management, including the CEO and the CFO, do not expect that our disclosure controls and procedures or our internal control over financial reporting will necessarily prevent all fraud or material errors. An internal control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations on all internal control systems, our internal control system can provide only reasonable assurance of achieving its objectives and no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within our Company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the control. The design of any system of internal control is also based in part upon certain assumptions about the likelihood of future events, and can provide only reasonable, not absolute, assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in circumstances, or the degree of compliance with the policies and procedures may deteriorate.
Changes in Internal Control over Financial Reporting
There were no changes in our internal control over financial reporting during the quarter ended March 31, 2023 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
Risk factors
As filed, 452 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Our short and long-term success is subject to many factors that are beyond our control. Investors and prospective investors should consider carefully information contained in this report and the risks and uncertainties described in “Part I—Item 1A—Risk Factors” of the Company’s Form 10-K for the fiscal year ended December 30, 2022. Such risks and uncertainties could materially adversely affect our business, financial condition or operating results.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2023-03-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2022-12-31 to 2023-03-31 | $73.5m | us-gaap:Revenues |
| Cost of revenue | 3 months2022-12-31 to 2023-03-31 | $16.0m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months2022-12-31 to 2023-03-31 | $57.6m | us-gaap:GrossProfit |
| Research and development | 3 months2022-12-31 to 2023-03-31 | $10.3m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2022-12-31 to 2023-03-31 | $54.8m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2022-12-31 to 2023-03-31 | $2.8m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months2022-12-31 to 2023-03-31 | $2.0m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2022-12-31 to 2023-03-31 | $2.7m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2022-12-31 to 2023-03-31 | $0.05 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2022-12-31 to 2023-03-31 | $0.06 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2022-12-31 to 2023-03-31 | 49,500,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 3 months2022-12-31 to 2023-03-31 | −$5.1m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months2022-12-31 to 2023-03-31 | $2.9m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2023-03-31 | $90.0m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2023-03-31 | $312.9m | us-gaap:AssetsCurrent |
| Total assets | At period end2023-03-31 | $418.9m | us-gaap:Assets |
| Current liabilities | At period end2023-03-31 | $47.1m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2023-03-31 | $80.0m | us-gaap:Liabilities |
| Shareholders' equity | At period end2023-03-31 | $338.9m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0000950170-23-017183. Last ingested by Listed: Nov 4, 2026, 17:00 ET. Listed shows no prices and gives no investment advice.